Health Economics and Outcomes Research (HEOR)

Health Economics and Outcomes Research (HEOR)

Led by Director and Principal Andrew Briggs, DPhil, and CEO John Schneider, PhD, AHE researchers and consultants have extensive knowledge and experience in the field of health economics and outcomes research (HEOR). These services include a wide variety of offerings across the product development continuum. In the early stages of development, we provide insights and analysis on potential market size and the design of rigorous economic evaluations, such as clinical studies and cost-effectiveness analysis. In later stages of development, we can offer more in-depth analyses to support expanded market access. For more information, view one of our past presentations on Establishing the Value of New Drugs, Devices, and Diagnostics.

Focus: HEOR Analytics

Traditional HEOR has focused mainly on model building, utility development, and so on. But as data sources have become more nuanced and complex, and product value pathways have become more intricate, there is a need to push the limits of HEOR by applying state-of-the art statistical analyses of data. To address this need, Avalon has developed a practice area within its HEOR capability called HEOR Analytics. These tasks include novel statistical analyses of HEOR data, such as trial data or quality of life data, and novel applications of those analyses to statistical and economic models.

We have extensive experience in advising health care leaders and managers in the following HEOR areas:

  • Evidence Planning & Study Design
  • Conceptual Models
  • Literature Synthesis & Meta-Analysis
  • Data Sourcing, Analysis & Interpretation
  • Economic Modeling, Cost Effectiveness Analysis & Budget Impact Analysis
  • Web-Based Graphical Model User Interfaces
  • Patient-Reported Outcomes & Utilities*
  • Market Access & Reimbursement
  • Payer & Purchaser Engagement
  • Peer-Reviewed Publications & Communications
  • Medical device total cost of ownership (TCO) analysis
  • Real-world data analysis using large datasets, including Truven, Pharmetrics, Medicare claims data, etc.
  • Support to Value Analysis Teams (VAT) & Value Analysis Committees (VACs) for hospitals & health systems**
  • Hospital Value Analysis (HVA) of medical devices**
  • Clinical research monitoring and study coordination
  • Predictive Analytics & Forecasting**
  • Market Research**
  • Market Development & Expansion**
  • Investor Research & Analysis**
  • Benchmarking Reimbursement & Performance Metrics**

* Provided through a collaborative partnership with Acaster-Lloyd Consulting.

**For European markets, also provided through our collaborative partnership with Oberender.

Recent Publications

SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer. 2018

Effect of theophylline as adjunct to inhaled corticosteroids on exacerbations in patients with COPD: a randomized clinical trial. 2018

Behavioural activation versus guided self-help for depression in adults with learning disabilities: the BeatIt RCT. 2018

Comparison between high-sensitivity cardiac troponin T and cardiac troponin I in a large general population cohort. 2018

Long-term weight loss following a randomised controlled trial of a weight management programme for men delivered through professional football clubs: the Football Fans in Training follow-up study. 2018

A decision-analytic model to assess the cost-effectiveness of etelcalcetide vs. cinacalcet. 2018

Enhancing the value of the ASCO value framework. 2018

3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial. 2018

Rationale and design of the British Heart Foundation (BHF) Coronary Microvascular Angina (CorMicA) stratified medicine clinical trial. 2018

A decision framework for treating chronic immune thrombocytopenia with thrombopoietin receptor agonists. 2018

High-Sensitivity Troponin T and Incident Heart Failure in Older Men: British Regional Heart Study. 2018

Highest risk-highest benefit’ strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies. 2018

Long-term weight loss trajectories following participation in a randomised controlled trial of a weight management programme for men delivered through professional football clubs: A longitudinal cohort study and economic evaluation. 2018

The feasibility of a randomised-controlled trial to compare the cost-effectiveness of palliative cardiology or usual care in people with advanced heart failure: two exploratory prospective cohorts. 2018

Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction. 2018

Cost-effectiveness of umeclidinium compared with tiotropium and glycopyrronium as monotherapy for chronic obstructive pulmonary disease: a UK perspective. 2018

EQ-5D-5L: Smaller steps but a major step change? 2018.

Health impacts of the WIAT programme to improve local woodlands for deprived urban communities : a quasi-experimental study. 2018

Estimating the Long-Term Outcomes Associated With ImmunoOncology Therapies: Challenges and Approaches for Overall Survival Extrapolations. 2018

Economic evaluation of procalcitonin-guided antibiotic therapy in acute respiratory infections: a Chinese hospital system perspective. 2017

Do NOT follow this link or you will be banned from the site!